[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112013021896A2 - inibidores de serina/treonina cinase - Google Patents

inibidores de serina/treonina cinase

Info

Publication number
BR112013021896A2
BR112013021896A2 BR112013021896A BR112013021896A BR112013021896A2 BR 112013021896 A2 BR112013021896 A2 BR 112013021896A2 BR 112013021896 A BR112013021896 A BR 112013021896A BR 112013021896 A BR112013021896 A BR 112013021896A BR 112013021896 A2 BR112013021896 A2 BR 112013021896A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
serine
threonine kinase
threonine
compositions
Prior art date
Application number
BR112013021896A
Other languages
English (en)
Inventor
Allen A Thomas
Allison L Marlow
Christopher S Siedem
Eli Wallace
Gabrielle R Kolakowski
Huifen Chen
Jacob Schwarz
James F Blake
Jason Demeese
John J Gaudino
Li Ren
Mark Joseph Chicarelli
Peter J Mohr
Robert J Kaus
Rustam Garrey
Steven Mark Wenglowsky
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of BR112013021896A2 publication Critical patent/BR112013021896A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

inibidores de serina/treonina cinase. compostos tendo a fórmula i, em que z, z^ 1^, z^ 2^, z^ 3>, r^ 3^, r^ 3a^, r^ 3b^ e r^ b^, e como definido aqui, são inibidores de erk cinase. são também descritas composições e métodos para tratar distúrbio hiperproliferativos.
BR112013021896A 2011-02-28 2012-02-28 inibidores de serina/treonina cinase BR112013021896A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161447587P 2011-02-28 2011-02-28
PCT/US2012/027009 WO2012118850A1 (en) 2011-02-28 2012-02-28 Serine/threonine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112013021896A2 true BR112013021896A2 (pt) 2016-11-08

Family

ID=45852719

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013021896A BR112013021896A2 (pt) 2011-02-28 2012-02-28 inibidores de serina/treonina cinase

Country Status (11)

Country Link
US (1) US9133187B2 (pt)
EP (1) EP2681215B1 (pt)
JP (1) JP6085866B2 (pt)
KR (1) KR101961500B1 (pt)
CN (1) CN103635472B (pt)
BR (1) BR112013021896A2 (pt)
CA (1) CA2828478C (pt)
ES (1) ES2543050T3 (pt)
MX (1) MX339873B (pt)
RU (1) RU2013143839A (pt)
WO (1) WO2012118850A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013021896A2 (pt) 2011-02-28 2016-11-08 Array Biopharma Inc inibidores de serina/treonina cinase
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
EP2723717A2 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
US9187462B2 (en) * 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
JP2015504054A (ja) * 2011-12-27 2015-02-05 バイオ−ファーム ソリューションズ カンパニー リミテッド 多発性硬化症の治療または予防に使用されるフェニルカルバメート化合物
PL3321262T3 (pl) 2012-03-01 2021-06-28 Array Biopharma, Inc. Inhibitory kinaz serynowo/treoninowych
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
RU2644947C2 (ru) 2012-08-27 2018-02-15 Аррэй Байофарма Инк. Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний
MX2015003535A (es) 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.
KR20150068956A (ko) 2012-10-16 2015-06-22 에프. 호프만-라 로슈 아게 세린/트레오닌 키나아제 억제제
JPWO2015012328A1 (ja) * 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
BR112016012844B1 (pt) 2013-12-06 2023-01-10 Genentech, Inc Composto e composições farmacêuticas
CN105848723B (zh) * 2013-12-30 2019-08-02 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
CN105980387B (zh) * 2013-12-30 2019-04-19 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
JP2019518426A (ja) 2016-04-15 2019-07-04 ジェネンテック， インコーポレイテッド がんの診断及び治療方法
JP7039489B2 (ja) * 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
AU2018329925A1 (en) 2017-09-08 2020-03-05 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
US11053217B2 (en) 2017-09-29 2021-07-06 Mitsubishi Tanabe Pharma Corporation Optically active pyrrolidine compound and method for producing same
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
BR112021017957A2 (pt) 2019-03-28 2021-11-23 Jiangsu Hengrui Medicine Co Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
AU2020251621A1 (en) 2019-03-29 2021-11-04 Jiangsu Hengrui Medicine Co., Ltd. Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
JP2022534224A (ja) 2019-05-24 2022-07-28 江蘇恒瑞医薬股▲ふん▼有限公司 置換縮合二環式誘導体、その調製方法、および医薬におけるその適用
TW202110837A (zh) * 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
CN111170929A (zh) * 2019-12-12 2020-05-19 北京达因高科儿童药物研究院有限公司 一种由末端烯烃制备β-氨基醇的方法
WO2022064009A1 (en) 2020-09-25 2022-03-31 Janssen Pharmaceutica Nv Cyclin-dependent kinase 7 (cdk7) non-covalent inhibitors
CN116437915A (zh) 2020-09-29 2023-07-14 江苏恒瑞医药股份有限公司 一种吡咯并杂环类衍生物的晶型及其制备方法
CN115040522B (zh) * 2022-06-30 2024-02-06 牡丹江医学院 一种用于治疗肺癌的药物及其制备方法
WO2024088296A1 (zh) * 2022-10-25 2024-05-02 上海拓界生物医药科技有限公司 哌啶并嘧啶类衍生物、其制备方法及其在医药上的应用
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT672042E (pt) 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP2002514196A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジノンおよびピリドン化合物ならびに使用方法
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
EP1261327B1 (en) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US7026326B2 (en) 2002-05-21 2006-04-11 Amgen Inc. Substituted heterocyclic compounds and methods of use
AU2003251869A1 (en) * 2002-07-15 2004-02-02 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
AU2005232745A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006021458A2 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
AU2006236387A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
US20100022531A1 (en) * 2005-09-01 2010-01-28 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
DE602007009932D1 (de) 2006-02-16 2010-12-02 Schering Corp Pyrrolidin-derivate als erk-hemmer
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
WO2008023239A1 (en) 2006-08-23 2008-02-28 Pfizer Products Inc. Pyrimidone compounds as gsk-3 inhibitors
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
WO2008115890A2 (en) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009011904A1 (en) * 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
ES2535166T3 (es) 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
WO2009061761A2 (en) 2007-11-06 2009-05-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic amines
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CA2729327C (en) 2008-06-27 2016-10-11 Xenon Pharmaceuticals Inc. Heterocyclic derivatives that modulate the activity of stearoyl-coa desaturase
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
DK2370413T3 (en) 2008-12-08 2015-11-02 Arena Pharm Inc Modulators of prostacyclin (PG12) receptor, which can be used for the treatment of disorders related to this
BR112013021896A2 (pt) 2011-02-28 2016-11-08 Array Biopharma Inc inibidores de serina/treonina cinase
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
PL3321262T3 (pl) 2012-03-01 2021-06-28 Array Biopharma, Inc. Inhibitory kinaz serynowo/treoninowych
RU2644947C2 (ru) 2012-08-27 2018-02-15 Аррэй Байофарма Инк. Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний

Also Published As

Publication number Publication date
EP2681215B1 (en) 2015-04-22
CA2828478A1 (en) 2012-09-07
KR101961500B1 (ko) 2019-03-22
MX339873B (es) 2016-06-15
EP2681215A1 (en) 2014-01-08
CA2828478C (en) 2019-12-31
ES2543050T3 (es) 2015-08-14
US20130338140A1 (en) 2013-12-19
JP6085866B2 (ja) 2017-03-01
JP2014506930A (ja) 2014-03-20
MX2013009877A (es) 2014-02-11
CN103635472B (zh) 2018-01-12
US9133187B2 (en) 2015-09-15
WO2012118850A1 (en) 2012-09-07
KR20140014190A (ko) 2014-02-05
CN103635472A (zh) 2014-03-12
RU2013143839A (ru) 2015-04-10

Similar Documents

Publication Publication Date Title
BR112013021896A2 (pt) inibidores de serina/treonina cinase
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34559A (es) Inhibidores de bromodominios
EA201591497A1 (ru) Новые производные октагидропирроло[3,4-c]пиррола и их аналоги в качестве ингибиторов аутотаксина
PH12014502169A1 (en) N-cyclylamides as nematicides
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
UY34765A (es) Compuestos novedosos.
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
EA201491456A1 (ru) Соединения-ингибиторы raf
UY34039A (es) Compuestos fungicidas
UY33925A (es) Inhibidores tricíclicos de quinasas
PH12016501071B1 (en) Serine/threonine kinase inhibitors
UY34648A (es) Amidas como inhibidores de pim
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34515A (es) Triazolopiridinas sustituidas
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
UY34329A (es) Compuestos de triazolopiridina
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
UY33976A (es) Derivados de pirazolo-pirimidina.
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
UY34038A (es) Esteres aromaticos para composiciones agroquimicas.
MY178583A (en) Hydantoin derivative

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements